(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2022 (30.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/140245 A1

(51) International Patent Classification:
A61K 31/05 (2006.01) *A61K 47/18* (2017.01)
A61K 47/10 (2017.01)

(21) International Application Number:
PCT/US2021/064325

(22) International Filing Date:
20 December 2021 (20.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/128,447 21 December 2020 (21.12.2020) US

(71) Applicant: **ISOSCELES PHARMACEUTICALS, INC.** [US/US]; 1213 Culbreth Drive, Suite 359, Wilmington, North Carolina 28405 (US).

(72) Inventor: **LANIER, Brett Jackson**; c/o Isosceles Pharmaceuticals, Inc., 1213 Culbreth Drive, Suite 359, Wilmington, North Carolina 28405 (US).

(74) Agent: **MILLS, E. Eric**; Nexsen Pruet, PLLC, 4141 Parklake Avenue, Suite 200, Raleigh, North Carolina 27612 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: PARENTERAL CANNABINOID FORMULATIONS AND USES THEREOF

(57) Abstract: Provided herein are non-toxic parenteral pharmaceutical formulations comprising at least one cannabinoid, typically cannabinol. The cannabinoids can be from plant sources or synthetically prepared. Methods for preparing such formulations and methods for using such formulations are also disclosed. Such methods of use include, without limitation, intravenous administration of the present formulations for the treatment of peri-operative pain. The present formulations may provide potential a replacement of, or adjuvant for dosage reduction, of opioids for acute and chronic pain management.

WO 2022/140245 A1